Inventiva (NASDAQ:IVA) Reaches New 52-Week High – Still a Buy?

Shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA) hit a new 52-week high on Friday . The stock traded as high as $6.55 and last traded at $6.49, with a volume of 85139 shares traded. The stock had previously closed at $6.30.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. HC Wainwright assumed coverage on Inventiva in a report on Wednesday, September 3rd. They issued a “buy” rating and a $20.00 target price for the company. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $20.00 target price on shares of Inventiva in a report on Tuesday, September 30th. Guggenheim upped their target price on Inventiva from $9.00 to $13.00 and gave the stock a “buy” rating in a report on Tuesday, September 2nd. Piper Sandler assumed coverage on Inventiva in a report on Wednesday, August 27th. They issued an “overweight” rating and a $26.00 target price for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inventiva in a report on Saturday, September 27th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $15.57.

Inventiva Price Performance

The firm has a 50 day moving average price of $4.90 and a two-hundred day moving average price of $3.85.

Institutional Investors Weigh In On Inventiva

A hedge fund recently bought a new stake in Inventiva stock. Wealth Enhancement Advisory Services LLC purchased a new stake in Inventiva S.A. Sponsored ADR (NASDAQ:IVA) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 10,715 shares of the company’s stock, valued at approximately $32,000. Institutional investors own 19.06% of the company’s stock.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.